Photocure set for 2012 completion of Phase II Cevira trial for cervical HPV
This article was originally published in Scrip
Executive Summary
Norway's Photocure is preparing the ground to progress its photodynamic therapy for cervical human papilloma virus (HPV) infection, Cevira, into Phase III having begun enrolment into a Phase II trial evaluating the optimal dose and safety of the product. "The study is designed to be the study that will form the platform for the final Phase III program of Cevira, and the results of the [Phase II] trial are anticipated in the second half 2012," the company said.